Secondary resistance to sonidegib is rare in locally advanced basal cell carcinoma. [PDF]
J Eur Acad Dermatol VenereolResistència secundària; Carcinoma basocel·lular localment ...
Muñoz Couselo E +5 more
europepmc +7 more sources
Locally advanced basal cell carcinoma: Real‐life data with sonidegib [PDF]
Dermatologic Therapy, 2022 In recent years, the category of hedgehog pathway inhibitor (HHI) has shown great results in patients with advanced basal cell carcinoma (aBCC), but few real-life data on efficacy and safety profile of sonidegib are available. We report our management of locally advanced BCCs (laBCCs) with sonidegib, also describing the favorable response of locally ...
Ludovica Toffoli +6 more
openaire +4 more sources
Sonidegib for the Treatment of Advanced Basal Cell Carcinoma [PDF]
Frontiers in Oncology, 2020 Basal cell carcinoma (BCC) accounts for almost 80% of skin cancers, and its healthcare workload burden is substantial within dermatology departments. Although most BCCs are small, well-defined tumors amenable of surgery or conservative procedures, in a ...
Gabriella Brancaccio +4 more
doaj +3 more sources
Locally Advanced Basal Cell Carcinoma with Intraocular Invasion. [PDF]
Open Access Maced J Med Sci, 2018 We present a 103 - year - old patient, with duration of complaints of about ten years. The initial complaint had been presented as a small nodule, located on the eyebrow, which subsequently ulcerated and encompassed larger regions of the upper and lower eyelids.
Tchernev G +4 more
europepmc +4 more sources
Dermatology Reports, 2021 Background: The management of difficult-to-treat periocular basal cell carcinoma becomes very challenging in cases of delayed diagnosis, leading to the development of locally advanced basal cell carcinoma. Objective: The aim of this study was to evaluate
Vincenzo De Giorgi +13 more
doaj +3 more sources
Vismodegib: The Proof of Concept in Basal Cell Carcinoma
Clinical Medicine Insights: Oncology, 2014 Although basal cell carcinoma (BCC) is the most common cancer worldwide, its metastatic dissemination is exceptional. Before 2012, we had a few treatment options available for metastatic or locally advanced cases.
Narjiss Berrada +3 more
doaj +2 more sources
Management of Locally Advanced Basal Cell Carcinoma with Sonic Hedgehog Pathway Targeted Therapy: A Case Report and Discussion [PDF]
Case Reports in DermatologyIntroduction: Basal cell carcinoma (BCC) is the most common skin malignancy in the world. While most lesions are treated using surgical methods, others may present as locally advanced or metastatic disease and are not amenable to surgical therapy alone ...
Neal Ferrin +3 more
doaj +2 more sources
The safety and efficacy of sonidegib for the treatment of locally advanced basal cell carcinoma [PDF]
Expert Review of Anticancer Therapy, 2016 Basal cell carcinomas (BCCs) are the commonest malignancy in the Western world. Locally advanced BCCs (laBCCs) represent tumours that have developed in difficult-to-treat facial sites, aggressively recurrent tumours, large neglected tumours and those in which current treatment options are excluded by clinical or patient-driven criteria. It is estimated
Faisal R Ali, John T Lear
exaly +3 more sources
Clinical Features and Outcomes of Locally Advanced and Metastatic Basal Cell Carcinoma
Acta Dermato-VenereologicaCutaneous basal cell carcinoma (BCC) is a primarily indolent tumour that is easily cured. However, locally advanced BCC (laBCC) and metastatic BCC can have a poor prognosis.
Anna A.J.H. Zwanenburg +5 more
doaj +4 more sources
Sonidegib treatment in patients with locally advanced basal cell carcinoma. [PDF]
Dermatol Ther, 2022 Villani A, Fabbrocini G, Scalvenzi M.
europepmc +5 more sources